Drug interaction study tests liver enzyme effects on cancer treatment

NCT ID NCT05072106

Completed Knowledge-focused Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how bosentan, a drug that affects liver enzymes, changes the levels of the cancer drug lurbinectedin in the blood. Eleven adults with advanced solid tumors received lurbinectedin alone and with bosentan. The goal was to see if bosentan alters how the body processes lurbinectedin, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lurbinectedin and bosentan
What this could lead to: If successful, this could help doctors understand how to safely combine lurbinectedin with other drugs that affect liver enzymes.
What could go wrong: This is a very small, early-phase study focused on drug levels, not treatment effectiveness. Results may not apply to larger populations or show any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Fundación Jiménez Diaz

Madrid, 28040, Spain
Hospital de Sanchinarro

Madrid, 28050, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.